Kimberly J. Popovits has served on our board of directors since April 2026. Ms. Popovits has served as a Senior Advisor to Blackstone Life Sciences since 2020. She served as President and Chief Executive Officer of Genomic Health, Inc., a publicly traded healthcare company, from January 2009, and as Chairman of the Board of Genomic Health, Inc. from March 2012, until the acquisition of Genomic Health, Inc. by Exact Sciences Corporation in November 2019. Ms. Popovits previously served as President and Chief Operating Officer of Genomic Health from February 2002 to January 2009. Prior to leading Genomic Health, Ms. Popovits served as Senior Vice President, Marketing and Sales at Genentech, Inc. ( Genentech ). During her 15 years at Genentech, Ms. Popovits led the successful commercialization of 14 new therapies. Ms. Popovits currently serves on the board of directors of 10x Genomics, Inc. and Kiniksa Pharmaceuticals International, plc. Ms. Popovits served on the board of directors of Talis Biomedical Corporation, a publicly-traded biotechnology company, from 2020 to 2025, where she also served as Interim Chief Executive Officer from August 2021 to November 2021. She previously served on the board of directors of MyoKardia, Inc., a publicly-traded biopharmaceutical company that was subsequently acquired by Bristol Myers Squibb and Exact Sciences. She holds a B.A. in Business from Michigan State University. The Board considered Ms. Popovits's senior executive roles in publicly traded life sciences companies, her extensive experience and strong background in executive leadership at commercial-stage companies, as well as her service on the boards of directors of numerous publicly held biotechnology companies, in concluding that she is qualified to serve as a director.